NSEOutcome of Board Meeting6h ago · 23 Jul 2026, 01:17 pm
Outcome of Board Meeting
Solara Active Pharma Sciences Limited · SOLARA
✦ AI SummaryResults
Solara Active Pharma Sciences Limited has informed the exchange about the outcome of its board meeting held on July 23, 2026, where the board considered and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report for the said period.
Attachments (1)
📄pdf
Download →
SOLARA_23072026131622_SE_FIling_Outcome.pdf
View document text
Corporate Office:
Solara Active Pharma Sciences Limited
TICEL Bio Park, 6th Floor,
Module No. 601, 602, 603, Phase II – CSIR Road,
Taramani, Chennai, Tamil Nadu – 600113.
Tel: +91 44 4344 6700
Fax: +91 44 47406190
E-mail: investors@solara.co.in
Website: www.solara.co.in
Date: July 23, 2026
The BSE Limited The National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G, Bandra-Kurla
Dalal Street, Mumbai – 400 001 Complex, Bandra (E), Mumbai – 400 051
Scrip Code: 541540, 890202 Symbol: SOLARA, SOLARAPP1
Dear Sir/Madam,
Sub: Outcome of Board Meeting held on July 23, 2026 and submission of Unaudited Financial Results
(Standalone and Consolidated) for the quarter ended June 30, 2026, as per Regulation 30 and 33
of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing
Regulations”)
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
(“SEBI Listing Regulations”), we hereby inform you that the Board of Directors of the Company at their
meeting held today i.e. July 23, 2026, have considered and approved the Unaudited Financial Results
(Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, together with the Limited
Review Report issued by M/s. Deloitte Haskins & Sells, Chartered Accounts, Statutory Auditor of the
Company. A copy of the Unaudited Financial Results along with the Limited Review Report has been
enclosed herewith.
Please note that the aforesaid unaudited Financial Results will also be available on the Company's website at
https://solara.co.in/investor-relations/financial-information.
The Board Meeting commenced at 12:00 P.M and concluded at 01:05 P.M.
This is for your information and records.
Thanking you,
Yours faithfully,
For Solara Active Pharma Sciences Limited
Pooja Jaya Kumar
Company Secretary & Compliance Officer
Membership No.: A57415
Encl.: As above
Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636
Registered Office: 9th Floor, ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 / Tel: +91-22- 2087 0033